SCHEMBL4428101

SCHEMBL4428101

O=C(O)c1ccc(-c2ccc(F)cc2)c(O)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2L1 Q07817 1/20 0.62
BAD Q92934 1/20 0.62
KDM4E B2RXH2 3/20 0.53
CA1 P00915 2/20 0.53
CA2 P00918 2/20 0.53
CA12 O43570 1/20 0.53
POLB P06746 1/20 0.53
GAA P10253 1/20 0.53
MAPT P10636 1/20 0.53
CA4 P22748 1/20 0.53
CA6 P23280 1/20 0.53
PTGS2 P35354 1/20 0.53
CA7 P43166 1/20 0.53
CA9 Q16790 1/20 0.53
CA14 Q9ULX7 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
LMNA P02545 2/20 0.51
HSD17B10 Q99714 2/20 0.51
MAP4K4 O95819 1/20 0.51
MEN1 O00255 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26981142 0.90 KDM4E (0.64) KDM4ECA1CA2CA12POLB
SCHEMBL3238016 0.88 CA12 (0.61) BCL2L1BADKDM4ECA1CA2
SCHEMBL19404312 0.87 BCL2L1 (0.60) BCL2L1BADKDM4ECA1CA2
SCHEMBL26572449 0.85 BCL2L1 (0.62) BCL2L1BADKDM4ECA1CA2
SCHEMBL28211489 0.85 HSD17B10 (0.58) KDM4ECA1CA2CA12POLB
SCHEMBL11540874 0.84 PTGS1 (0.54) BCL2L1BADKDM4EGAAMAPT
SCHEMBL3663963 0.82 POLB (0.59) BCL2L1KDM4ECA1CA2CA12
SCHEMBL2943490 0.82 BCL2L1 (0.58) BCL2L1BADKDM4EGAAL3MBTL1
SCHEMBL2558827 0.81 HSD17B1 (0.57) KDM4ECA1CA2CA12POLB
SCHEMBL5937383 0.81 SRD5A2 (0.58) KDM4ECA1CA2CA12POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7538121-B2 Vanilloid receptor modulators GLAXO GROUP LIMITED (GB) 2009-05-26 US disclosed
EP-2033953-A1 Vanilloid receptor modulators Glaxo Group Limited (GB) 2009-03-11 EP disclosed
US-20060142333-A1 Vanilloid receptor modulators MACDONALD GREGOR J 2006-06-29 US disclosed
EP-1480954-A1 VANILLOID RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2004-12-01 EP disclosed
WO-2003068749-A1 VANILLOID RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2003-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060142333-A1 Vanilloid receptor modulators TRPV1, NPSR1, TRPV3 BCL2L1 4308/4885BAD 3011/4885KDM4E 3923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.